Skip to main content
SpringerLink
Log in

Suicide and Antidepressants

  • Published:
Drugs Aims and scope Submit manuscript

Summary

Depression is associated with a risk of suicide 13 to 30 times greater than in the general population, and antidepressants are among the drugs most frequently implicated in fatal overdose, resulting in a dilemma for the clinician. Suicidal thoughts are a core symptom of depression, and there is evidence that the selective serotonin (5-hydroxytryptamine) reuptake inhibitors (SSRIs), including fluvoxamine, are of particular benefit in reducing their occurrence. Data from controlled studies indicate that the SSRIs do not exacerbate suicidal ideation; on the contrary, SSRIs protect against the emergence of suicidal thoughts, which reflect the natural history of the disease. The SSRIs also appear to be particularly effective in patients who are highly suicidal at treatment initiation, and to be more effective than the tricyclic antidepressants in treating severe depression and improving anxiety symptoms associated with depression.

Thus, fluvoxamine, in common with other SSRIs, is of particular benefit in treating depression in patients with prominent suicidal thoughts or who are at increased risk of suicide.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Beasley CM, Dornseif BE, Bosomworth JC, Sayler ME, Rampey AH, et al. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. British Medical Journal 303: 685–692, 1991

    Article  PubMed  Google Scholar 

  • Bielski RJ, Friedel RO. Prediction of tricyclic antidepressant response. Archives of General Psychiatry 33: 1479–1489, 1976

    Article  PubMed  CAS  Google Scholar 

  • Bulusu L, Alderson M. Suicides 1950–1982. Office of Population Censuses and Surveys HMSO, London. Population Trends 35: 11–13, 1984

    Google Scholar 

  • Committee on Safety of Medicines. Benzodiazepines, dependence and withdrawal symptoms. Current Problems 21: 1988

  • Dasgupta K. Additional case of suicidal ideation associated with fluoxetine. American Journal of Psychiatry 147: 1570, 1990

    Google Scholar 

  • Delay J, Deniker P, Lemperiere T, Ginestet D. Deux années d’experience de l’imipramine. Annales Medico-Psychologiques 1: 235–249, 1961

    Google Scholar 

  • den Boer JA, Westenberg GM. Effects of serotonin and noradrenaline uptake inhibitors in panic disorders: a double-blind comparative study with fluvoxamine and maprotiline. International Clinical Psychopharmacology 3: 59–74, 1988

    Article  Google Scholar 

  • Feuerstein TJ, Jakisch R. Why do some antidepressants provoke suicide? Psychopharmacology 90: 422, 1986

    Article  PubMed  CAS  Google Scholar 

  • Guyotat J, Lambert PA. L’imipramine. In Actualités therapeutiques psychiatriques, pp. 261–271, Masson, Paris, 1963

    Google Scholar 

  • Guze SB, Robins E. Suicide among primary affective disorders. British Journal of Psychiatry 117: 437–438, 1970

    Article  PubMed  CAS  Google Scholar 

  • Hagnell O, Lanke J, Rorsman B. Suicide rates in the Lundby study: mental illness as a risk factor for suicide. Neuropsychobiology 7: 248–253, 1981

    Article  PubMed  CAS  Google Scholar 

  • Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 23: 55–62, 1960

    Google Scholar 

  • Markowitz JS, Weissman MM, Ouellette R, Lish JD, Klerman GL. Quality of life in panic disorder. Archives of General Psychiatry 46: 984–992, 1989

    Article  PubMed  CAS  Google Scholar 

  • Masand P, Gupta S, Dewan M. Suicidal ideation related to fluoxetine treatment. New England Journal of Medicine 324: 420, 1991

    PubMed  CAS  Google Scholar 

  • Montgomery SA. The efficacy of fluoxetine as an antidepressant in the short and long term. International Clinical Psychopharmacology 4 (Suppl. 1): 113–119, 1989

    PubMed  Google Scholar 

  • Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134: 382–389, 1979

    Article  PubMed  CAS  Google Scholar 

  • Montgomery SA, Cronholm B, Åsberg M, Montgomery D. Differential effects on suicidal ideation of mianserin, maprotiline and amitriptyline. British Journal of Clinical Pharmacology 5: 77S–80S, 1978

    Article  PubMed  Google Scholar 

  • Montgomery SA, Dunbar GC, Rasmussen JGC. Paroxetine aspects of safety. Presented at IV World Congress of Biological Psychiatry, Florence, 1991

  • Montgomery SA, Lambert MT, Lynch SPJ. The risk of suicide with antidepressants. International Clinical Psychopharmacology 3 (Suppl. 2): 15–24, 1988

    PubMed  Google Scholar 

  • Montgomery SA, McAuley R, Rani SJ, Roy D, Montgomery D. A double-blind comparison of zimelidine and amitriptyline in endogenous depression. Acta Psychiatrica Scandinavica 63 (Suppl. 290): 314–327, 1981a

    Article  Google Scholar 

  • Montgomery SA, Pinder RM. Do some antidepressants promote suicide? Psychopharmacology 92: 265–266, 1987

    Article  PubMed  CAS  Google Scholar 

  • Montgomery SA, Rani SJ, McAuley R, Roy D, Montgomery DB. The antidepressant efficacy of zimeldine and maprotiline. Acta Psychiatrica Scandinavica 63 (Suppl. 290): 219–224, 1981b

    Article  Google Scholar 

  • Muijen M, Roy D, Silverstone T, Mehmet A, Christie M. A comparative clinical trial of fluoxetine, mianserin and placebo with depressed outpatients. Acta Psychiatrica Scandinavica 78: 384–390, 1988

    Article  PubMed  CAS  Google Scholar 

  • Rouillon F, Phillips R, Serrurier E, Ansart E, Gerard MJ. Prophylactic efficacy of maprotiline on relapses of unipolar depression. Encephale XV 6: 527–534, 1989

    Google Scholar 

  • Starkey IR, Lawson AAH. Psychiatric aspects of acute poisoning with tricyclic and related antidepressants. A ten year review. Scottish Medical Journal 25: 303–308, 1980

    PubMed  CAS  Google Scholar 

  • Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. American Journal of Psychiatry 147: 207–210, 1990

    PubMed  CAS  Google Scholar 

  • Vollrath M, Angst J. Outcome of panic and depression in a seven-year follow-up: results of the Zurich study. Acta Psychiatrica Scandinavica 80: 591–596, 1989

    Article  PubMed  CAS  Google Scholar 

  • Wakelin J. The role of serotonin in depression and suicide. Advances in Biological Psychiatry 17: 70–83, 1988

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Academic Department of Psychiatry, St Mary’s Hospital Medical School, Praed Street, London, W2 1NY, England

    Stuart A. Montgomery

Authors
  1. Stuart A. Montgomery
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Montgomery, S.A. Suicide and Antidepressants. Drugs 43 (Suppl 2), 24–31 (1992). https://doi.org/10.2165/00003495-199200432-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199200432-00005

Keywords

Search

Navigation